Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 5/20 | 0.51 |
| ▸ | NPY1R | P25929 | 4/20 | 0.51 |
| ▸ | NPY2R | P49146 | 3/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886319 | 1.00 | OPRK1 (0.57) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL20363350 | 0.98 | OPRK1 (0.57) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL24001215 | 0.98 | OPRK1 (0.55) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL21886334 | 0.98 | OPRK1 (0.54) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL21286542 | 0.98 | OPRK1 (0.54) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL21886578 | 0.97 | OPRK1 (0.54) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL21886577 | 0.97 | OPRK1 (0.55) | OPRK1KISS1RCPB1CPB2CHRNB2 | |
| SCHEMBL24360473 | 0.97 | OPRK1 (0.53) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL24360489 | 0.97 | OPRK1 (0.53) | OPRK1KISS1RCPB1CPB2NPY4R | |
| SCHEMBL24001211 | 0.97 | OPRK1 (0.53) | OPRK1KISS1RCPB1CPB2NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885KISS1R 1051/4885CPB1 1389/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885KISS1R 1051/4885CPB1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.